RODMAN&RENSHAW upgraded shares of Omeros (NASDAQ:OMER - Free Report) to a strong-buy rating in a research report report published on Thursday morning,Zacks.com reports.
Several other research firms also recently commented on OMER. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a report on Thursday. Rodman & Renshaw began coverage on Omeros in a report on Thursday. They issued a "buy" rating and a $9.00 target price on the stock. Cantor Fitzgerald reissued a "neutral" rating on shares of Omeros in a report on Thursday. Finally, StockNews.com downgraded Omeros from a "hold" rating to a "sell" rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $9.00.
Get Our Latest Research Report on OMER
Omeros Price Performance
OMER stock traded down $0.20 during midday trading on Thursday, hitting $6.75. The stock had a trading volume of 1,940,901 shares, compared to its average volume of 466,138. The firm has a market cap of $391.14 million, a price-to-earnings ratio of -2.89 and a beta of 1.47. The business has a 50-day moving average of $4.08 and a two-hundred day moving average of $4.07. Omeros has a 52-week low of $1.38 and a 52-week high of $7.51.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets lifted its holdings in shares of Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 7,016 shares in the last quarter. MML Investors Services LLC lifted its holdings in Omeros by 19.2% in the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company's stock valued at $74,000 after acquiring an additional 3,000 shares during the period. SPC Financial Inc. bought a new position in Omeros in the third quarter valued at about $77,000. SG Americas Securities LLC bought a new position in Omeros in the third quarter valued at about $80,000. Finally, Oppenheimer & Co. Inc. bought a new position in Omeros in the first quarter valued at about $85,000. 48.79% of the stock is owned by institutional investors.
About Omeros
(
Get Free Report)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Featured Stories
Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
